According to BeInCrypto, AstraZeneca’s stock price rose after the company reported that its third quarter earnings exceeded forecasts. In addition, AstraZeneca announced a $1.5 billion savings plan intended to support its AI‑backed pipeline.
The earnings result came in Q3 of the current fiscal year, and the savings plan is positioned to fund development work linked to artificial intelligence technologies within the drugmaker’s pipeline.
